GE Healthcare Life Sciences

Policy for discontinuation of BioProcess™ and Cell and Gene Therapy products

GE Healthcare is committed to continuing supplies of each of its BioProcess and Cell and Gene Therapy products as long as any such products are knowingly used in an approved, registered process for the manufacturing of human biopharmaceuticals and vaccines.

The following notification periods will apply if GE Healthcare decides to discontinue a product which, to the best of our knowledge, is no longer used in the manufacture of a human biopharmaceutical or vaccine:

- For any bulk chromatography resin product, (including ReadyToProcess chromatography resin) customers shall be notified at least 3 years in advance.
- For single-use disposable products (ReadyToProcess products, Wave cell bags, Xcellerex bags and connectors, and process scale filtration products) the notification period for discontinuation will be minimum 1 year in advance.
- For standard cell culture products, the notification period for discontinuation will be minimum 1 year in advance.
- For BioProcess chromatography instruments and columns, a Change Control Notification will be sent out when production of the instrument or column is discontinued. (For spare parts on instruments and columns installed by GE Healthcare an End-of-Service notification will be sent to all customers 1 year before the Service support period ends.)
- For cell and gene therapy products (e.g. Xuri, Sefia, Sepax) the notification period for discontinuation will be minimum 1 year in advance.

GE Healthcare reserves the right to discontinue a product within shorter notice time if and when regulatory or other legal reasons prevent its manufacture or distribution.

This policy applies to products for which subscription to change control notification is available on the web page www.gelifesciences.com/rsf

Emmanuel Ligner President and CEO	Olivier Loeillot General Manager BioProcess	Catarina Flyborg General Manager Cell & Gene therapy
13 September 2018	13 September 2018	13 September 2018